Facilitating Drug Development with In Situ FT-IR and Data-Rich Experimentation

Register Free: http://www.spectroscopyonline.com/spec_w/data_rich_tools

Event Overview:

Join us for this webcast to learn how in situ Fourier-transform infrared spectroscopy (FT-IR) and other novel tools are being deployed in the pharmaceutical industry to facilitate and accelerate drug development and synthesis.

Recent advances in the biocatalytic retrosynthetic toolbox have transformed the way the pharmaceutical company Merck conceives of novel synthetic routes, particularly for drug candidates with significant structural similarity to naturally occurring biomolecules. In this presentation, we will showcase how collaborative efforts across Process R&D at Merck are contributing towards building deep, fundamental understanding of a key intermediate in the synthesis of a new drug candidates. We will highlight past and ongoing efforts centering on enzyme discovery and reaction engineering, underpinned by data-rich experimentation (DRE) methods including; high-throughput experimentation and analysis, automation, and in situ reaction analysis using novel analytical tools, including FT-IR. Furthermore, development of a robust process optimized for a commercially relevant synthetic chemistry reactor will be reviewed including demonstration across scales.

Key Learning Objectives:

• How end-to-end automation enables experimental execution and data capture.
• How to ensure reaction performance across scales
• High-density, data-rich, time-course reaction analysis is critical to gaining deep process understanding

Speaker: Shane Grosser, Senior Principal Scientist, Merck

Time and date: Tues, Sept. 1, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

On demand available after airing until Sept. 1, 2021.

Sponsor: Mettler Toledo

Register Free: http://www.spectroscopyonline.com/spec_w/data_rich_tools